SETH WOODRUFF: Open Payments
NPI 1760794408 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,250 in 202 payments from 20 companies in 2025. Trend: 2023 $2,276 · 2024 $2,153 · 2025 $3,250
Food & beverage: $3,250
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 30 | $538 |
| Alkermes, Inc. | 25 | $413 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $275 |
| ABBVIE INC. | 23 | $240 |
| Neurocrine BioSciences, Inc. | 15 | $238 |
| Vanda Pharmaceuticals Inc. | 12 | $237 |
| Braeburn Inc. | 13 | $204 |
| Corium, LLC | 13 | $189 |
| Tris Pharma Inc | 11 | $179 |
| Teva Pharmaceuticals USA, Inc. | 11 | $164 |
Products named: REXULTI, CAPLYTA, ARISTADA, VRAYLAR, INGREZZA, FANAPT, BRIXADI, Azstarys.
Industry payments across LA — which companies pay providers there.
